QNZ46 is primarily utilized in research settings, particularly in the field of neuroscience and pharmacology. It is known for its role as a selective inhibitor of NMDA receptors, specifically targeting the GluN2C and GluN2D subunits. This makes it a valuable tool for studying the function and regulation of these receptor subtypes in various neurological processes. Researchers use QNZ46 to investigate its potential effects on synaptic plasticity, neuronal communication, and conditions such as epilepsy, neurodegenerative diseases, and chronic pain. Its application helps in understanding the mechanisms underlying these conditions and in the development of targeted therapeutic strategies.